The Supreme Court made a shocking pro-abortion decision but left the door wide open for pro-lifers

The courts are filling up with abortion-related cases.

Ever since the U.S. Supreme Court overturned Roe v. Wade there has been a mixed bag of decisions on the issue.

And the Supreme Court just made a shocking pro-abortion decision but left the door open for pro-lifers.

The U.S. Supreme Court has ruled unanimously against several doctors and pro-life medical associations who brought a challenge to the chemical abortion pill mifepristone.

Not a ruling in favor of the deadly drug

But the ruling wasn’t the big victory for the pro-abortion lobby that the mainstream media is claiming.

In fact, in FDA v. Alliance for Hippocratic Medicine, the Supreme Court simply held that the doctors did not have standing to challenge the U.S. Food and Drug Administration’s (FDA) decision to discard safety regulations for the deadly chemical abortion pill. 

The court did recognize that the plaintiffs have “sincere legal, moral, ideological, and policy objections to elective abortion and to FDA’s relaxed regulation of mifepristone,” as Justice Brett Kavanaugh wrote in the majority ruling.

But the court went on to say that those objections are not enough to show the doctors would be injured by the FDA’s actions, noting the federal courts are “the wrong forum” for addressing their concerns.

“Under Article III of the Constitution, a plaintiff ’s desire to make a drug less available for others does not establish standing to sue,” Kavanaugh wrote. “Nor do the plaintiffs’ other standing theories suffice.”

Kavanaugh continued by writing that those who object to the abortion pill and its manner of regulation “may always take their concerns to the Executive and Legislative Branches and seek greater regulatory or legislative restrictions on certain activities.” 

Pro-lifers take to social media to denounce the decision

While not a total victory for the purveyors of the deadly chemical abortion drug, pro-lifers still took to social media to denounce the Court’s decision.

The case stemmed from an August 2023 Fifth Circuit Court of Appeals ruling that found that the FDA “failed to address several important concerns” when it loosened restrictions on the abortion drug mifepristone after 2016. 

But the appeals court narrowed an injunction issued by U.S. District Court Judge Matthew Kacsmaryk, who required the FDA to reverse its initial 2000 approval of the pill altogether.

The FDA had allowed distribution of mifepristone via mail and removed the initial in-person visit requirement in 2021. 

Earlier in 2016, it had rolled back other safety regulations, enabling the dangerous drug to be used through ten weeks of pregnancy rather than seven.  

The OB/GYNs and emergency room doctors who brought the challenge correctly pointed out that women are more likely to require medical treatment as a result of the FDA’s relaxed safety standards.

Pro-Life Press will keep you up-to-date on any developments to this ongoing story.

Leave a Reply

Your email address will not be published. Required fields are marked *